Stock Scorecard
Stock Summary for Avadel Pharmaceuticals plc (AVDL) - $15.83 as of 5/10/2024 7:48:17 PM EST
Total Score
5 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for AVDL
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for AVDL
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for AVDL
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 |
Bonus Criteria for AVDL
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for AVDL
Financial Details for AVDL
Company Overview |
|
|---|---|
| Ticker | AVDL |
| Company Name | Avadel Pharmaceuticals plc |
| Country | USA |
| Description | Avadel Pharmaceuticals plc is a biopharmaceutical company in the United States. The company is headquartered in Dublin, Ireland. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 12/31/2023 |
| Next Earnings Date | 7/31/2024 |
Stock Price History |
|
| Last Day Price | 15.83 |
| Last Day Price Updated | 5/10/2024 7:48:17 PM EST |
| Last Day Volume | N/A |
| Average Daily Volume | 1,072,425 |
| 52-Week High | 19.09 |
| 52-Week Low | 9.50 |
| Last Price to 52 Week Low | 66.63% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 114.24 |
| Sector PE | 93.69 |
| 5-Year Average PE | -16.91 |
| Free Cash Flow Ratio | 17.21 |
| Industry Free Cash Flow Ratio | 14.44 |
| Sector Free Cash Flow Ratio | 32.94 |
| Current Ratio Most Recent Quarter | 2.85 |
| Total Cash Per Share | 0.92 |
| Book Value Per Share Most Recent Quarter | 0.98 |
| Price to Book Ratio | 16.52 |
| Industry Price to Book Ratio | 6.21 |
| Sector Price to Book Ratio | 22.04 |
| Price to Sales Ratio Twelve Trailing Months | 51.79 |
| Industry Price to Sales Ratio Twelve Trailing Months | 17.08 |
| Sector Price to Sales Ratio Twelve Trailing Months | 7.83 |
Share Statistics |
|
| Total Shares Outstanding | 96,118,000 |
| Market Capitalization | 1,521,547,940 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Dividend Aristocrat? | False |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.40% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -16.59% |
| Reported EPS 12 Trailing Months | -2.00 |
| Reported EPS Past Year | -0.30 |
| Reported EPS Prior Year | -2.01 |
| Net Income Twelve Trailing Months | -156,834,000 |
| Net Income Past Year | -160,276,000 |
| Net Income Prior Year | -137,464,000 |
| Quarterly Revenue Growth YOY | -100.00% |
| 5-Year Revenue Growth | -44.07% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 88,789,000 |
| Total Cash Past Year | 105,111,000 |
| Total Cash Prior Year | 96,499,000 |
| Net Cash Position Most Recent Quarter | -4,350,000 |
| Net Cash Position Past Year | 13,497,000 |
| Long Term Debt Past Year | 91,614,000 |
| Long Term Debt Prior Year | 91,614,000 |
| Total Debt Most Recent Quarter | 93,139,000 |
| Equity to Debt Ratio Past Year | 0.49 |
| Equity to Debt Ratio Most Recent Quarter | 0.46 |
| Total Stockholder Equity Past Year | 87,739,000 |
| Total Stockholder Equity Prior Year | -21,145,000 |
| Total Stockholder Equity Most Recent Quarter | 78,384,000 |
Options |
|
| Put/Call Ratio | 0.12 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.22 |
| MACD Signal | 0.46 |
| 20-Day Bollinger Lower Band | 12.36 |
| 20-Day Bollinger Middle Band | 15.53 |
| 20-Day Bollinger Upper Band | 18.69 |
| Beta | 1.63 |
| RSI | 39.05 |
| 50-Day SMA | 13.96 |
| 200-Day SMA | 9.01 |
System |
|
| Modified | 5/10/2024 6:22:44 PM EST |